CY1109984T1 - Παραλλαγες gla πεδιου παραγοντα vii ή viia - Google Patents

Παραλλαγες gla πεδιου παραγοντα vii ή viia

Info

Publication number
CY1109984T1
CY1109984T1 CY20101100374T CY101100374T CY1109984T1 CY 1109984 T1 CY1109984 T1 CY 1109984T1 CY 20101100374 T CY20101100374 T CY 20101100374T CY 101100374 T CY101100374 T CY 101100374T CY 1109984 T1 CY1109984 T1 CY 1109984T1
Authority
CY
Cyprus
Prior art keywords
factor vii
viia
gla
field
human factor
Prior art date
Application number
CY20101100374T
Other languages
Greek (el)
English (en)
Inventor
Jesper Mortensen Haaning
Kim Vilbour Andersen
Claus Bornaes
Original Assignee
Bayer Healthcare, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare, Llc filed Critical Bayer Healthcare, Llc
Publication of CY1109984T1 publication Critical patent/CY1109984T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
CY20101100374T 2003-06-19 2010-04-23 Παραλλαγες gla πεδιου παραγοντα vii ή viia CY1109984T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47978003P 2003-06-19 2003-06-19
DKPA200400930 2004-06-15
EP04738925A EP1644504B8 (en) 2003-06-19 2004-06-18 Factor vii or viia gla domain variants

Publications (1)

Publication Number Publication Date
CY1109984T1 true CY1109984T1 (el) 2014-09-10

Family

ID=33553697

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100374T CY1109984T1 (el) 2003-06-19 2010-04-23 Παραλλαγες gla πεδιου παραγοντα vii ή viia

Country Status (23)

Country Link
US (5) US20050164932A1 (enExample)
EP (1) EP1644504B8 (enExample)
JP (2) JP4915918B2 (enExample)
KR (1) KR101191779B1 (enExample)
CN (1) CN1839203B (enExample)
AT (1) ATE458057T1 (enExample)
AU (2) AU2004247799B2 (enExample)
BR (1) BRPI0411650A (enExample)
CA (1) CA2529828C (enExample)
CY (1) CY1109984T1 (enExample)
DE (1) DE602004025576D1 (enExample)
DK (1) DK1644504T3 (enExample)
ES (1) ES2338425T3 (enExample)
HR (1) HRP20100264T1 (enExample)
IL (1) IL172364A (enExample)
MX (1) MXPA05013769A (enExample)
NZ (2) NZ573412A (enExample)
PL (1) PL1644504T3 (enExample)
PT (1) PT1644504E (enExample)
RU (1) RU2373282C2 (enExample)
SI (1) SI1644504T1 (enExample)
WO (1) WO2004111242A1 (enExample)
ZA (1) ZA200600539B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806063B2 (en) 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
PL1781782T3 (pl) 2004-08-17 2010-10-29 Csl Behring Gmbh Zmodyfikowane polipeptydy zależne od witaminy K
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
US20070129298A1 (en) * 2005-07-22 2007-06-07 Maxygen Holdings, Ltd. In-solution activation of factor vii
JP5894722B2 (ja) 2005-09-01 2016-03-30 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
SI2147096T1 (sl) 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
PL3165232T3 (pl) * 2012-12-24 2019-12-31 Coagulant Therapeutics Corporation Krótko działające polipeptydy czynnika VII
FI3524617T3 (fi) 2013-03-15 2023-06-26 Gladiator Biosciences Inc Gla-domeenit terapeuttisina aineina
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
PE20171380A1 (es) 2014-12-10 2017-09-15 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
US20190153119A1 (en) * 2016-04-14 2019-05-23 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with neovascularization
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
KR20200050961A (ko) 2017-09-05 2020-05-12 글래디에이터 바이오사이언시스 인코포레이티드 줄기세포로의 페이로드의 전달
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1991011519A1 (en) 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
AU651573B2 (en) * 1990-01-29 1994-07-28 Novo Nordisk Health Care Ag Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
ES2109336T3 (es) * 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
EP0575464B1 (en) 1991-02-28 2004-08-11 Zymogenetics, Inc. Modified factor vii
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
HU219682B (hu) 1993-05-21 2001-06-28 Novo Nordisk A/S. Módosított VII faktor
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5847085A (en) * 1996-11-08 1998-12-08 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE69916306T2 (de) 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
AU1262900A (en) 1998-11-06 2000-05-29 Novo Nordisk A/S Method for the production of fvii
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6806063B2 (en) * 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
MXPA03001984A (es) * 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
HUP0301246A3 (en) 2000-09-13 2005-12-28 Novo Nordisk Healthcare Ag Human coagulation factor vii variants
HUP0301267A3 (en) * 2000-10-02 2005-12-28 Novo Nordisk Healthcare Ag Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
JP4472526B2 (ja) 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa

Also Published As

Publication number Publication date
PL1644504T3 (pl) 2010-08-31
AU2010200793B2 (en) 2013-04-04
DK1644504T3 (da) 2010-05-25
EP1644504B8 (en) 2010-06-02
CA2529828A1 (en) 2004-12-23
EP1644504A1 (en) 2006-04-12
US20070117756A1 (en) 2007-05-24
US20050164932A1 (en) 2005-07-28
KR20060022283A (ko) 2006-03-09
ES2338425T3 (es) 2010-05-07
AU2010200793A1 (en) 2010-03-25
ZA200600539B (en) 2006-12-27
RU2006101391A (ru) 2006-06-10
US20060240526A1 (en) 2006-10-26
CA2529828C (en) 2013-01-15
AU2004247799B2 (en) 2009-12-03
JP4915918B2 (ja) 2012-04-11
JP2012105650A (ja) 2012-06-07
US20060241041A1 (en) 2006-10-26
EP1644504B1 (en) 2010-02-17
BRPI0411650A (pt) 2006-08-08
AU2004247799A1 (en) 2004-12-23
US8987202B2 (en) 2015-03-24
NZ573412A (en) 2010-09-30
HRP20100264T1 (hr) 2010-08-31
PT1644504E (pt) 2010-03-22
CN1839203B (zh) 2011-11-16
US7807638B2 (en) 2010-10-05
NZ544728A (en) 2009-04-30
KR101191779B1 (ko) 2013-01-14
RU2373282C2 (ru) 2009-11-20
US20060252128A1 (en) 2006-11-09
WO2004111242A1 (en) 2004-12-23
HK1095357A1 (en) 2007-05-04
CN1839203A (zh) 2006-09-27
DE602004025576D1 (de) 2010-04-01
MXPA05013769A (es) 2006-03-08
JP5580283B2 (ja) 2014-08-27
SI1644504T1 (sl) 2010-06-30
ATE458057T1 (de) 2010-03-15
IL172364A (en) 2014-01-30
JP2006527982A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
MXPA06003474A (es) Agonistas de receptores de melanocortina.
BR0116470A (pt) éteres de imidazoquinolina substituìdos com uréia
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
MXPA02009567A (es) Benzoilpirzoles y su uso como herbicidas.
UA85559C2 (en) Aminobenzophenone compounds
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE69901569D1 (de) Humane antikörper gegen faktor ix/ixa
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
SE0302304D0 (sv) Novel compounds
ATE417856T1 (de) Motilidverbindungen
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
IL162600A0 (en) Cc-chemokine mutants as cc-chemokine antagonists
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
BRPI0415355A (pt) triarilimidazóis
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
DE60003074D1 (de) Fusidinsäure-derivate
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen